Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Advanced Bioinformatics Lecture 1: Introduction to system biology ZHU FENG [email protected] http://idrb.cqu.edu.cn/ Innovative Drug Research Centre in CQU 创新药物研究与生物信息学实验室 Table of Content 1. An introduction 2. How to survive 3. What will be covered 4. Signaling pathway 5. Concluding remarks 2 Lecture: ZHU FENG Major: Bioinformatics and computer-aided drug design 2006-2013: System biology-based drug discovery 1999-2013: Computational simulation on biological system Please visit http://idrb.cqu.edu.cn/ to download the teaching material 3 4 5 Introduction to this module Credits 32 Schedule 10 lectures (week 4th, 6th to 10th, 3 months) Methods English-teaching & Project-based (3 projects) 1. Biological pathway simulation 2. Computer-aided anti-cancer drug design 3. Disease-causing mutation on drug target 6 Whether will you pass the exam? It depends! But tell you the way to survive One long presentation (40%, team work) The organization; Team-work spirit; Achievement …… One short presentation (20%, personal) Clearance; The organization …… One project report (40%, individual effort) My observation (1. actively involved in every course; 2. come to this module on time; 3. creativity; 4. do not just listen, get familiar with the biological side of the topic; 5.good relationship with me ……) Your ways of putting what you have done in English 7 What will be covered? Guaranteed! To learn the most-widely used bioinformatics tools • Basic understanding of the method in each tool (Normally required in a college module) • Capable of explaining the algorithm to a layperson (so that you are perceived as an expert!) • Knowing the application range and limitation of each tool (now the real expert!) To learn through project, focused on application and problem solving • Study of real and recently-emerged biological problems in system biology: 1. pathways simulation; 2. drug design; 3. drug target mutation (give you the experience to work for a life-science lab or a pharmaceutical company). 8 Lab and Text Book “Open-lab” policy: • Our lab assignments only uses internet tools and downloadable software (which means that you can do the projects “any-time, any-place”) • No need to show-up in the lab, as long as you submit lab-report on time. • Project-report submission system at: http://idrb.cqu.edu.cn/ Textbook: • As most of the topics are not covered by existing textbooks, you are not required to have a textbook. Recommended reference books: Introduction to Bioinformatics. Arthur M. Lesk. 2002. Oxford University Press; ISBN: 0199251967 Bioinformatics: The Machine Learning Approach (Adaptive Computation and Machine Learning). Pierre Baldi, Soren Brunak. 2001. The MIT Press; ISBN: 026202506X Molecular modelling : principles and applications. Andrew R. Leach. Imprint Harlow, England Most importantly: literature from PubMed (http://www.ncbi.nlm.nih.gov/pubmed) 9 Topics covered Lecture 1: Introduction to system biology (week 4th) An introduction How to survive What will be covered Signaling pathway Concluding remarks Lecture 2: Cancer pathways and therapeutics (week 6th) The nature of cancer How cancer arises Pathway involved in cancer Cell cycle clock and cancer Molecular target of cancer 10 Topics covered Lecture 3: Protein-protein interaction (week 7th) Protein-protein interaction Interaction representations Method A: Two-hybrid assay Method B: Affinity purification Spoke and matrix models of PPI Lecture 4: Short presentation A (week 8th) Opening remarks G1: Student 11; Student 12 G2: Student 21; Student 22 G3: Student 31; Student 32 Concluding remarks 11 Topics covered Lecture 5: Signal transduction and simulation (week 9th) Components in signal transduction Growth factor and receptor RTK signal transduction Constructing a pathway model Signaling oncogene & therapeutics Lecture 6: Pharmacology and drug development (week 10th) Modern drug development Drug & corresponding target Mechanism of drug binding Mechanism of drug action Adrenoceptor cardiac function 12 Topics covered Lecture 7: Computer-aided lead identification (week 11st) Schematic of DOCKing Pharmacophore-based docking INVDOCK Strategy Ligand-based drug design Classification of drugs by SVM Lecture 8: Short presentation B (week 12nd) Opening remarks G1: Student 13; Student 14 G2: Student 23; Student 24 G3: Student 33; Student 34 Concluding remarks 13 Topics covered Lecture 9: Drug resistant & cancerous mutation (week 13rd) • Differential drug efficacy • Pharmacogenetics • Pharmacogenetic response • Drug resistance mutation • Prediction of drug resistance Lecture 10: Examination and presentation (week 14th) • Opening remarks • G1: Biological pathway simulation • G2: Computer-aided drug design • G3: Cancerous mutations on targets • Concluding remarks 14 Generic signaling pathway Signal Receptor (sensor) Transduction Cascade Targets Response Metabolic Enzyme Gene Regulator Cytoskeletal Protein Altered Metabolism Altered Gene Expression Altered Cell Shape or Motility 15 Integrated circuit of the cell 16 EGFRERK/MAPK Signaling Pathways 17 Single target drug EGFR MET Cancer growth Multi-target drug PDGF R EGFR MET PDGF R Cancer growth stop C.L. Sawyers. Nature. 449(7165):993-996 (2007) Z. Chen. Journal of Medicinal Chemistry. 54(10):3650-3660 (2011) Gleevec: “Time magazine” reported as the “magic bullet” for anti-caner, which is a typical multi-target drug for Abl, Kit, Arg, PDGFR 18 Signaling Synergy effect (1+1>2) on system level Therapeutic effect Pharmacodynamic combination Anti-counteractive Complementary Facilitating Pharmacokinetic combination Potentiative 19 Cisplatin: DNA adduct, DNA damage, Cancer cell apoptosis Trastuzumab: Anti-HER2 antibody Synergy effect: Pietras et al. Oncogene 1998 Le et al. J. Biol. Chem. 2005 Lee et al. Cancer Res. 2002 DNA repair Anti-anti-caner Anti-counteractive synergistic effect 20 Methotrexate (MTX) – 5-FU Combination Anticancer S. Loi. Journal of Clinical Oncology. 31(7):860-867 (2013) Complex can enhance the interaction between 5FU and TS Drug-drug interaction Complementary 21 Up regulate RANKL Human T cell exposed to gp120 突厥蔷薇 Rosa damascena Anti-HIV active ingradent Kaempferol AIDS-058145 Synergy Effect Fakruddin et al. Clin. Exp. Immunol. (2004) Kaempferol Direct inhibit HIV protease AIDS-058145 Inhibit HIV protease Up regulate HIV Transcription substrate 22 Quantitative study not qualitative EGFR pathway net work (cancer related) ERK’s activation dynamics will directly affect the cell proliferation and differentiation, and push tumor genesis. Therefore, the understanding of EGFR-ERK pathway will understand how cancer signaling is proceed and developed. 23 1. Single protein ODE equation concentration (time) 2. Soleving the equations together 3. Sensitivity analysis, multi-targets synergy effect 24 Examples EGF binding to EGF receptor EGF∙EGFR dimerization Reaction rate producing EGF∙EGFR Reaction rate consuming EGF∙EGFR Determine the change in the concentration of EGF∙EGFR over time 25 Parameters Gene expression level for different disease Gene expression level for individual Kinetic data for protein-protein interaction 26 Is quantitative study reliable? Model Validation 1: EGFR L858R/T790M mutation in lung cancer significantly hamper EGFR-Cbl interaction (Kf), therefore reduce EGFR endocytosis, and lead to the elongation of EGFR-ERK signal in lung cancer cell. Oncogene, 26 (2007), pp. 6968–6978 Kf 27 Is quantitative study reliable? Model Validation 2: The initial concentration of EGF in cancer cell line PC12 is 50ng/ml, transient activation of ERK (peaks within 5 min and decays within 30–60 min) Nat. Cell Biol., 7 (2011), pp. 365–373 Protein phosphatase 2A (PP2A, from 0.005 to 0.01 μM) that differ by 2-folds show little effect on the change of maximal amount of active ERK but substantially affect the duration of ERK activation Biophys. J., 87 (2009), pp. L01–L02 28 Enjoy more on the next lecture 1. Biological pathway simulation 2. Computer-aided anti-cancer drug design 3. Disease-causing mutation on drug target Any questions? Thank you! 29